ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. and Ra Pharmaceuticals have entered a collaboration to develop Cyclomimetics, a class of compounds having the diversity and specificity of antibodies while retaining attributes of small-molecule drugs. Under the agreement, Ra will use its Extreme Diversity platform to develop Cyclomimetic candidates for protein targets in multiple therapeutic areas. Ra is eligible to receive up to $200 million, including unspecified up-front payments, research funding, and milestones.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X